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Abstract
Background: Maintaining tight glycemic control is important for prevention of diabetes-related outcomes in end-
stage renal disease patients with diabetes, especially in light of their poor prognosis. This study aimed to determine
factors associated with poor glycemic control among U.S. patients with diabetes mellitus initiating hemodialysis for
end-stage renal disease.
Methods: Using data from the U.S. Renal Data System, electronic health records of a large national dialysis provider,
and U.S. Census data, we performed a cross-sectional multivariable Poisson regression analysis to characterize risk
factors associated with poor glycemic control, defined as glycated hemoglobin (HbA1c) >7 vs. ≤7 %, in adult patients
with diabetes who initiated hemodialysis at an outpatient facility between 2006 and 2011.
Results: Of 16,297 patients with diabetes, 21.2 % had HbA1c >7 %. In multivariable analysis, younger patients, patients
of Native American race, and those of Hispanic ethnicity had higher prevalence of poor glycemic control. Independent
correlates of poor glycemic control further included higher platelet count, white blood cell count, and ferritin; higher
body mass index, systolic blood pressure, total cholesterol and triglyceride concentrations; lower HDL and albumin
concentrations; lower normalized protein catabolic rate; and higher estimated glomerular filtration rate at initiation of
dialysis (all P < 0.05). No independent associations were found with area-level socioeconomic indicators. Occurrence of
diabetes in patients <40 years of age, a proxy for type 1 diabetes, was associated with poor HbA1c control compared
with that in patients ≥40 years of age, which was classified as type 2 diabetes. These findings were robust to the
different outcome definitions of HbA1c >7.5 % and >8 %.
Conclusion: In this cohort of incident end-stage renal disease patients with diabetes, poor glycemic control was
independently associated with younger age, Native American race, Hispanic ethnicity, higher body mass index, and
clinical risk factors including atherogenic lipoprotein profile, hypertension, inflammation, and markers indicative of
malnutrition and a more serious systemic disease.
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Background
Diabetes mellitus is the leading cause of end-stage renal
disease (ESRD) and accounts for 30–50 % of incident
ESRD cases [1]. Previous studies have shown that patients
with diabetes and ESRD requiring dialysis have higher
rates of several comorbidities and experience poorer clin-
ical outcomes compared with patients without diabetes.
Glycemic control in these patients has been shown to be
associated with microvascular and macrovascular compli-
cations and mortality [2–4]. Point-of-care glycated
hemoglobin (HbA1c) is commonly used as a marker for
long-term glycemic control that reflects average blood
glucose concentration over approximately 3 months in pa-
tients with diabetes [5, 6]. Monitoring and improving gly-
cemic control is essential to diabetes care and
management in order to delay the progression of micro-
and macrovascular complications related to diabetes [7].
Improved glycemic control may reduce the risk of
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myocardial infarction and cardiovascular death [8],
and improve survival in dialysis patients with diabetes
[9]. According to the Kidney Disease Outcomes Quality
Initiative Clinical Practice Guideline for Diabetes and
Chronic Kidney Disease, HbA1c levels of 7–9 % have been
shown to be associated with better clinical outcomes in
hemodialysis patients, though this relationship has not
been supported by all observational studies, and data from
prospective, randomized studies are lacking [10]. Still
these guidelines suggest that patients with diabetes who
are on dialysis may benefit from intensive glycemic con-
trol (HbA1c ≤ 7 %) due to reduction in the incidence of
microvascular complications [10].
There are limited data on risk factors for suboptimal gly-
cemic control in patients with diabetes requiring mainten-
ance hemodialysis. Maintaining optimal glycemic levels is
difficult in these patients because they often present with
other comorbidities and clinical conditions that could con-
tribute to poor glycemic control [11]. From a clinical and a
health policy perspective, understanding the various socio-
demographic and clinical factors impacting glycemic con-
trol in hemodialysis patients with diabetes is important, as
this knowledge could help guide future studies and inter-
ventions to improve patient outcomes and access to quality
care. In the present study, we aimed to determine factors
associated with poor glycemic control in U.S. patients with
diabetes whose declining kidney function mandated initi-
ation of renal replacement therapy using hemodialysis.
Methods
Data source
We used data from the United States Renal Data System
(USRDS), the national registry for patients with ESRD
[12], and data from the electronic health records (EHR)
of DaVita, Inc., the second largest national provider of dia-
lysis services in the U.S. Information covering years 2006
to 2011 from both sources were merged using a crosswalk
of anonymized patient identifiers generated by the USRDS
Coordinating Center, with approval by the Centers for
Medicare and Medicaid Services (CMS) and the National
Institutes of Diabetes and Digestive and Kidney Disease
(NIDDK). The USRDS contains demographic data for al-
most all Americans with ESRD, data from final-action
Medicare claims (Parts A, B, D) for eligible patients, as
well as information on comorbidities. The DaVita EHR
provides highly granular and longitudinal data on labora-
tory values including HbA1c, all measured centrally, as
well as on vital signs and hemodialysis-related parameters,
all measured at the point of care.
Study population
Our study population included all adult patients
(≥18 years old) with incident ESRD between 2006 and
2011 whose Medical Evidence Report (form CMS-2728)
identified diabetes as a reported comorbidity or cause of
kidney disease. Using information from the USRDS Con-
densed Treatment History (RXHIST60) file, we restricted
the cohort to those who received their maintenance
hemodialysis treatments at a DaVita outpatient facility and
had no dialysis modality switches by day 90. We further
restricted the cohort to those who had Medicare fee-for-
service (Parts A + B) as their primary payer by 90 days
after initiation of hemodialysis, and excluded patients with
missing data on HbA1c, age, sex, race and ethnicity, and
other covariates in the multivariable model. This study
was approved by an institutional review board of Stanford
University and conducted in accordance with the Declar-
ation of Helsinki guidelines. Due to the unidentified nature
of the data, patient consent was not deemed necessary.
HbA1c measurements
We abstracted baseline HbA1c data obtained at the time
the patient initiated hemodialysis at a DaVita outpatient
facility (i.e., within 90 days of hemodialysis initiation)
from the DaVita EHR. Poor glycemic control was de-
fined as an HbA1c >7 %.
Predictor variables
Information on age, sex, reported race (white, black, Asian,
Native American, Pacific Islander, and other) and Hispanic
ethnicity, and reported comorbidities were obtained from
the Medical Evidence Report (form CMS-2728) in the
USRDS. Oral antidiabetic treatment was ascertained from
form CMS-2728 on which providers indicated whether a
patient required insulin, oral antidiabetic drugs, or neither.
Laboratory values, vital signs, and derived biometric pa-
rameters (normalized protein catabolic rate (nPCR); body
mass index (BMI)) were abstracted from the EHR. No in-
dividual level socioeconomic data were available in USRDS
or the EHRs. In order to address this lack of measures,
which may be important for predicting poor glycemic con-
trol at baseline, we obtained area-level socioeconomic data
from the U.S. Census Bureau American Community
Survey (ACS). We were constrained to use ZIP code as the
area of analysis in order to match the smallest indicator of
geography available in the registry data. While for some
outcomes ZIP code can lead to unstable associations due
to heterogeneity of characteristics within ZIP code, for
most outcomes examined, results have been shown to be
consistent with smaller census-defined levels of geography
[13]. ACS data were obtained for the following ZIP code
characteristics (table number): median rent (B25064), me-
dian household income (B19013), percent below poverty
(B06012), employment (B23001) and level of educational
attainment (B15002) using the R package “acs” version 1.2
within the R computing environment.
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Statistical analysis
We described baseline patient characteristics using means
and standard deviations for normally distributed continu-
ous variables, medians and interquartile ranges for non-
normally distributed data, and counts and proportions for
categorical data for the overall cohort as well as for cat-
egories of low (<5.5 %), moderate (5.5 to <7 %), and high
(≥7 %) levels of HbA1c.
We calculated prevalence ratios (PR) and their corre-
sponding 95 % confidence intervals (CI) using multivari-
able Poisson regression with robust variance to
characterize factors associated with poor glycemic con-
trol, which was defined as HbA1c >7 vs. ≤7 %. Variables
were chosen a priori as potential determinants of poor
glycemic control regardless of their statistical signifi-
cance. Each patient’s estimated glomerular filtration rate
(eGFR) was calculated from creatinine concentrations
reported at initiation of dialysis using the 4-variable
Modification of Diet in Renal Disease equation [14].
Age, platelet count, white blood cell count, and the five
socioeconomic variables were assessed in tertiles. All
other variables were modeled according to clinically rele-
vant categories. We performed univariate analyses then
two multivariable analyses: model 1 included demographic
and area-level socioeconomic variables, and model 2 in-
cluded all demographic, area-level socioeconomic, clinical
and biometric variables. We conducted sensitivity analyses
by redefining poorly controlled glycemic control as
HbA1c >7.5 % and >8 %. We also performed stratified
analyses by diabetes type. Data on specific type of diabetes
are not available in the USRDS. As such, we used age as a
surrogate for diabetes type and classified occurrence of
diabetes in patients younger than age 40 as type 1 dia-
betes, and that in patients ≥40 years of age as type 2 dia-
betes. This approach has been used in previous studies
[15]. Usually, we would conduct a series of tests for effect
modification to formally identify any differences among
individual associations between diabetes types. However,
the proportion of patients with type 1 diabetes was found
to be extremely small (4 %) and so any significant test for
effect modification would have more likely represented
false positive or chance findings rather than true differ-
ences in associations. Hence, we presented models strati-
fied by diabetes type without formally motivating this
action with tests for effect modification. All statistical tests
were two-sided and conducted at the 0.05 level of signifi-
cance, and all analyses were performed using SAS soft-
ware package, version 9.4 (SAS Institute Inc., Cary, NC).
Results
In the merged USRDS-DaVita crosswalk dataset, we
identified 127,571 adult patients with incident ESRD be-
tween 2006 and 2011 with diabetes as a reported comor-
bidity or cause of kidney disease. Of those, 79,617
patients received maintenance hemodialysis treatments
at a DaVita outpatient facility without a modality switch
by day 90. After excluding those who did not have Medi-
care fee-for-service (Parts A + B) as their primary payer
by 90 days after initiation of hemodialysis, and those
with missing data on HbA1c, age, race and ethnicity,
and other covariates, our final cohort included 16,297
patients (Fig. 1). The mean HbA1c in this cohort was
6.4 % and 21.2 % of patients had an HbA1c >7 %, with
the mean HbA1c in this group being 8.2 %, indicating
poorly controlled diabetes. Sociodemographic and clin-
ical characteristics of the overall cohort as well as by
HbA1c strata are shown in Table 1.
The mean age of patients in this cohort was 64.7 years.
Younger patients had higher HbA1c levels. The propor-
tions of men, Native Americans, Hispanics, and current
smokers increased in higher HbA1c categories. Several
comorbidities, except for cerebrovascular disease, hyper-
tension, and amputation, were more common in patients
with HbA1c between 5.5 and <7 % compared with those
with HbA1c <5.5 %. High HbA1c (>7 %) was correlated
with lower prevalence of cancer. Between low (≤5.5 %)
and moderate (5.5 to <7 %) HbA1c categories, there
were only small quantitative differences in area-level me-
dian rent and prevalence of individuals living below pov-
erty, unemployed, and those with less than high school
education. However, in the HbA1c ≥7 % category, pa-
tients lived in areas with lower median rent, and slightly
higher proportions lived under poverty and had less than
high school education.
In this cohort, 65.5 % of patients were insulin users,
27.0 % were on oral antidiabetic medications; 4.0 % were
on both insulin and oral antidiabetic medications,
whereas 9.4 % of the patients were on neither treatment.
The prevalence of insulin users as well those who used
both insulin and other oral antidiabetic medications in-
creased with higher levels of HbA1c, but the use of other
oral antidiabetic medications alone was more common
at low and moderate HbA1c levels.
Patients with higher HbA1c differed from those with
better glycemic control in terms of all clinical parame-
ters (all P < 0.05). Higher HbA1c was associated with
higher BMI, higher platelet and white blood cell counts,
higher lipid concentrations, blood pressure values, and
higher nPCR and eGFR. Higher HbA1c was associated
with lower ferritin concentrations.
The detailed results from the multivariable regression
on the outcome of uncontrolled diabetes (HbA1c >7 %)
are shown in Table 2. Compared with patients aged
57 years or younger, those aged 58–68 years had a 25 %
(95 % CI, 19 %, 30 %) and those aged 69 years or older
had a 47 % (95 % CI, 41 %, 52 %) lower prevalence of
poor glycemic control. Native American patients had a
42 % (95 % CI, 17 %, 72 %) higher prevalence of poor
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control compared with non-Hispanic whites, whereas
patients of Hispanic ethnicity had a 14 % (95 % CI, 3 %,
26 %) higher prevalence of poor glycemic control com-
pared with non-Hispanic whites. No associations were
identified between HbA1c control and sex, any of the
other race categories, or current smoking status. Poor
glycemic control was not associated with any of the five
area-level socioeconomic factors, and adjusting for vari-
ables on the potential causal pathway between these so-
cioeconomic factors and poor glycemic control did not
substantially change the findings.
Poor glycemic control was significantly associated with
markers of inflammation. Patients in the second and
third tertiles of platelet count had 10 and 15 % higher
prevalences of poor diabetes control, respectively, com-
pared with those in the lowest tertile. Patients in the sec-
ond and third tertiles of white blood cell count had 11
and 18 % higher prevalences of poor control, respect-
ively, compared with those in the lowest tertile. The PR
associated with ferritin concentration ≥400 ng/mL was
1.17 (95 % CI, 1.08, 1.27) compared with ferritin concen-
tration <200 ng/mL.
Components of metabolic syndrome were associated
with poor glycemic control. Patients with BMI ≥30 kg/m2
had a 10 % (95 % CI, 1 %, 21 %) higher prevalence of poor
glycemic control compared with those with BMI between
19 and <25 kg/m2. Worse lipid metabolism markers were
also associated with poor glycemic control. Patients with
total cholesterol ≥240 mg/dL and triglycerides ≥200 had
adjusted PRs of 1.12 (95 % CI, 1.01, 1.29) and 1.48
(95 % CI, 1.35, 1.61) respectively, whereas patients
with HDL ≥60 mg/dL had a 32 % (95 % CI, 24 %, 40 %)
lower prevalence of poor glycemic control compared with
those with HDL ≤40 mg/dL. Patients whose systolic blood
pressure was ≥140 mm Hg had a 12 % (95 % CI, 1 %,
26 %) higher prevalence of poor glycemic control com-
pared with those whose blood pressure was less than
120 mm Hg.
Fig. 1 Study population from the US Renal Data System and electronic health records of DaVita, Inc. We selected a cohort of patients 18 years of
age or older with incident ESRD between 2006 and 2011 and whose Medical Evidence Report (form CMS-2728) identified diabetes as a reported
comorbidity or cause of kidney disease. We restricted the cohort to those who received their maintenance hemodialysis treatments at a DaVita
outpatient facility and had no dialysis modality switches by day 90. We further restricted the cohort to those who had Medicare fee-for-service
(Parts A + B) as their primary payer by 90 days after initiation of hemodialysis, and excluded patients with missing data on HbA1c, age, sex, race
and ethnicity, and other covariates in the multivariable model
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Table 1 Sociodemographic and clinical characteristics of US adult patients with diabetes mellitus initiating maintenance
hemodialysisa
Variables HbA1c in Categories
All patients <5.5 % 5.5 to <7 % ≥7 % P-value
(N = 16,297) (N = 3399) (N = 9073) (N = 3825)
Patient characteristics
HbA1c (%), mean ± SD 6.4 ± 1.6 5.0 ± 0.3 6.2 ± 0.4 8.0 ± 2.5 <0.001
Demographics
Age (years), mean ± SD 64.7 ± 12.9 66.4 ± 12.6 65.8 ± 12.4 60.6 ± 13.4 <0.001
Male sex, N (%) 8817 (54.1) 1744 (51.3) 4997 (55.1) 2076 (54.3) <0.001
Race, N (%) <0.001
White 10,439 (64.1) 2158 (63.5) 5887 (64.9) 2394 (62.6)
Native American 376 (2.4) 56 (1.7) 185 (2.0) 135 (3.5)
Asian 483 (3.0) 108 (3.2) 274 (3.0) 101 (2.6)
Black 4842 (29.7) 1049 (30.9) 2629 (29.0) 1164 (30.4)
Pacific Islander 110 (0.7) 18 (0.5) 69 (0.8) 23 (0.6)
Other/Multiracial 47 (0.3) 10 (0.3) 29 (0.3) 8 (0.2)
Hispanic ethnicity, N (%) 2847 (17.5) 497 (14.6) 1552 (17.1) 798 (20.9) <0.001
Reported comorbidities, N (%)
Heart failure 6369 (39.1) 1251 (36.8) 3666 (40.4) 1452 (37.8) <0.001
Atherosclerotic heart disease 3924 (24.1) 735 (21.6) 2316 (25.5) 873 (22.8) <0.001
Cerebrovascular disease 1747 (10.7) 366 (10.8) 983 (10.8) 398 (10.4) 0.77
Peripheral vascular disease 2669 (16.4) 494 (14.5) 1531 (16.9) 644 (16.8) 0.005
Hypertension 14,486 (89.0) 3001 (88.3) 8082 (89.1) 3403 (89.0) 0.45
Amputation 743 (4.6) 137 (4.0) 417 (4.6) 189 (4.9) 0.17
Cancer 936 (5.7) 227 (6.7) 574 (6.3) 135 (3.5) <0.001
Current tobacco use 899 (5.5) 186 (5.5) 473 (5.2) 240 (6.3) 0.05
Socioeconomic variables
Median rent ($), mean ± SD 860.74 ± 272.49 867.67 ± 284.03 863.31 ± 271.87 848.47 ± 263.02 0.005
Median household income ($), mean ± SD 46,715 ± 16,970 46,569 ± 17,203 47,028 ± 17,107 46,102 ± 16,412 0.02
% below poverty, mean ± SD 17.9 ± 10.1 17.8 ± 10.0 17.6 ± 10.0 18.7 ± 10.3 <0.001
% unemployed, mean ± SD 6.3 ± 2.6 6.3 ± 2.7 6.2 ± 2.6 6.4 ± 2.5 0.007
% < high school education, mean ± SD 17.4 ± 10.8 16.9 ± 10.3 17.2 ± 10.7 18.4 ± 11.3 <0.001
Antidiabetic medication use, N (%)
Insulin 10,676 (65.5) 1795 (52.8) 5886 (64.9) 2995 (78.3) <0.001
Oral antidiabetic medications 4404 (27.0) 1141 (33.6) 2499 (27.5) 764 (20.0) <0.001
Both insulin and oral antidiabetic medications 427 (4.0) 71 (4.0) 230 (3.9) 126 (4.2) <0.001
No medications 1528 (9.4) 519 (15.3) 853 (9.4) 156 (4.1) <0.001
Laboratory measurements
Body mass index (kg/m2), mean ± SD 30.3 ± 7.8 29.6 ± 7.6 30.4 ± 7.8 30.7 ± 8.0 <0.001
Platelet count (×103/μL), median
(25th–75th percentile)
236.0 (186.0–296.0) 226.0 (174.0–285.0) 235.0 (186.0–294.0) 245.0 (198.0–311.0) <0.001
White blood cell count (x1000/mm3), mean ± SD 7.6 ± 2.6 7.3 ± 2.6 7.6 ± 2.6 7.9 ± 2.7 <0.001
Ferritin (ng/mL), mean ± SD 365.5 ± 342.8 370.0 ± 347.1 373.4 ± 343.9 343.1 ± 335.4 <0.001
Total cholesterol (mg/dL), median
(25th–75th percentile)
143.0 (118.0–173.0) 138.0 (115.0–166.0) 141.0 (116.0–171.0) 153.0 (126.0–185.0) <0.001
LDL (mg/dL), median (25th–75th percentile) 72.0 (52.0–96.0) 70.0 (51.0–93.0) 71.0 (51.0–95.0) 77.0 (56.0–103.0) <0.001
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eGFR at initiation of hemodialysis was positively asso-
ciated with poor glycemic control. Compared with pa-
tients with eGFR less <7 mL/min/1.73 m2, those with
eGFR between 7 and 10 mL/min/1.73 m2 had a 16 %
(95 % CI, 4 %, 29 %) higher prevalence, and those with
eGFR ≥10 mL/min/1.73 m2 had a 38 % (95 % CI, 25 %,
53 %) higher prevalence of poor glycemic control. Albu-
min and nPCR were inversely associated with poor HbA1c
control (P < 0.05 for both), but hemoglobin was not inde-
pendently associated with poor glycemic control.
These findings were robust to the different outcome
definitions of HbA1c >7.5 % (12 % of patients) and >8 %
(8 % of patients) used in sensitivity analyses. The point
estimates of PR were similar for all the variables except
white blood cell count, which lost statistical significance
with a higher cutoff of HbA1c >8 %.
Toward conducting stratified analyses by diabetes type,
we found that 627 patients or approximately 4 % of our
cohort were presumed to have had type 1 diabetes based
on their age. The mean age of patients with type 1 dia-
betes was 33.0 years (±4.6 years) and that of patients
with type 2 diabetes was 66.0 years (±11.4 years). Pa-
tients with type 1 diabetes had a 61 % (95 % CI, 4 %,
84 %) higher prevalence of poor HbA1c control com-
pared with those with type 2 diabetes. Findings among
patients with type 1 diabetes did not vary from those of
the overall cohort with the exception of variables such
as age, Native American race, Hispanic ethnicity, and
clinical variables such as BMI, white blood cell count,
ferritin, HDL, SBP, albumin, and nPCR, all of which
were no longer significantly associated with poor HbA1c
control (Table 3). Platelet count and eGFR were more
strongly associated with poor control among patients
with type 1 diabetes compared with those in the overall
cohort. We did not find any significant differences in
findings among patients with type 2 diabetes compared
with those in the overall cohort.
Discussion
In this large cohort of incident US hemodialysis patients
with diabetes mellitus, we found that poor glycemic con-
trol, defined as HbA1c >7 %, was more common in
younger patients and among Native American and His-
panic patients. Poor glycemic control was further associ-
ated with components of metabolic syndrome including
higher BMI, unfavorable lipid profile, uncontrolled blood
pressure, and with markers of inflammation, malnutri-
tion, and a more serious systemic disease.
The inverse relationship that we found between age
and poor glycemic control is consistent with the findings
of studies not restricted to the ESRD setting [16, 17]. In
stratified analyses by diabetes type, we found that occur-
rence of diabetes in patients <40 years of age, a proxy
for type 1 diabetes, was associated with poor HbA1c
control compared with that in patients ≥40 years of age,
which was classified as type 2 diabetes. These findings
suggest that there may be pathophysiologic differences
in relation to glycemic control between type 1 and type
2 diabetes, which are reflected in the differences we ob-
served in the association between age and glycemic con-
trol. Behavioral differences may also explain the
association between younger age and poorer glycemic
control. Older patients may feel more determined and
willing to adhere to their medication therapy or to adopt
a healthy lifestyle consisting of regular exercise and
healthy diet [18]. Another explanation could be that with
increasing age, relatively more compliant and appropri-
ate patients are selected to start dialysis treatment,
whereas those who are considered less suitable and less
likely to maintain diabetic control opt for conservative
ESRD treatment without undergoing dialysis [19, 20]. It
is also possible that the lower HbA1c levels observed in
older patients is due to lower caloric intake and/or mal-
nutrition, which have been shown to be associated with
low HbA1c in the elderly, indicative of poor health and
Table 1 Sociodemographic and clinical characteristics of US adult patients with diabetes mellitus initiating maintenance
hemodialysisa (Continued)
HDL (mg/dL), median (25th–75th percentile) 38.0 (31.0–48.0) 39.0 (31.0–49.0) 38.0 (30.0–47.0) 39.0 (32.0–50.0) <0.001
Triglycerides (mg/dL), median (25th–75th percentile) 135.0 (96.0–191.0) 123.0 (89.0–172.0) 135.0 (96.0–190.0) 148.0 (104.0–214.0) <0.001
Systolic blood pressure (mmHg), median
(25th–75th percentile)
150.0 (132.0–169.0) 147.0 (129.0–167.0) 149.0 (131.0–168.0) 153.0 (135.0–173.0) <0.001
Diastolic blood pressure (mm Hg), median
(25th–75th percentile)
75.0 (65.0–87.0) 75.0 (64.0–85.0) 75.0 (64.0–86.0) 78.0 (67.0–90.0) <0.001
Albumin (g/dL), mean ± SD 3.6 ± 0.5 3.5 ± 0.5 3.6 ± 0.5 3.5 ± 0.4 <0.001
Normalized protein catabolic rate (g/kg/d), mean ± SD 0.91 ± 0.32 0.88 ± 0.28 0.92 ± 0.32 0.93 ± 0.32 <0.001
Estimated GFRb (mL/min/1.73 m2), mean ± SD 11.4 ± 4.8 10.9 ± 4.9 11.4 ± 4.7 11.7 ± 4.7 <0.001
Hemoglobin (g/dL), mean ± SD 12.1 ± 1.5 12.0 ± 1.6 12.1 ± 1.5 12.3 ± 1.5 <0.001
aVariables are described using means and standard deviations for normally distributed continuous data, medians and 25th and 75th percentile values for
non-normally distributed data, and counts and proportions for categorical data
bGFR, glomerular filtration rate
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Table 2 Prevalence ratios of poor glycemic control (HbA1c >7 % vs. ≤7 %)a
Determinants Unadjusted models Model 1b Model 2c P-valued
Age (years)
≤ 57 1 1 1
58–68 0.69 (0.64, 0.74) 0.70 (0.65. 0.75) 0.75 (0.70, 0.81) <0.001
≥ 69 0.47 (0.43, 0.51) 0.48 (0.44, 0.53) 0.53 (0.48, 0.59) <0.001
Male sex 1.01 (0.94, 1.08) 0.96 (0.90, 1.03) 1.07 (0.99, 1.15) 0.06
Race/ethnicitye
Native American 1.56 (1.30, 1.88) 1.41 (1.17, 1.71) 1.42 (1.17, 1.72) <0.001
Asian 0.89 (0.72, 1.10) 0.94 (0.76, 1.17) 0.97 (0.78, 1.21) 0.78
Black 1.04 (0.97, 1.12) 1.01 (0.92, 1.10) 1.02 (0.93, 1.12) 0.64
Pacific Islander 0.96 (0.63, 1.47) 0.87 (0.57, 1.33) 0.93 (0.61, 1.43) 0.75
Other/Multiracial 0.82 (0.41, 1.64) 0.80 (0.40, 1.59) 0.75 (0.38, 1.50) 0.41
Hispanic ethnicity 1.29 (1.19, 1.40) 1.16 (1.05, 1.28) 1.14 (1.03, 1.26) 0.01
Median rent ($)
≤ 735 1 1 1
736–959 0.93 (0.86, 1.01) 0.92 (0.84, 1.01) 0.93 (0.85, 1.01) 0.10
≥ 960 0.94 (0.86, 1.02) 0.95 (0.86, 1.05) 0.98 (0.88, 1.08) 0.68
Median household income ($)
< 38,629 1 1 1
38,630–52,301 0.99 (0.91, 1.08) 1.12 (0.98, 1.28) 1.09 (0.98, 1.20) 0.11
> 52,303 0.93 (0.86, 1.01) 1.08 (0.98, 1.20) 1.11 (0.97, 1.27) 0.13
% below poverty
< 12 1 1 1
12–21 1.15 (1.05, 1.25) 1.07 (0.96, 1.19) 1.06 (0.95, 1.19) 0.28
≥ 21 1.22 (1.13, 1.33) 1.09 (0.94, 1.26) 1.09 (0.94, 1.27) 0.24
% unemployed
< 5 1 1 1
5–7 1.08 (0.99 1.18) 1.04 (0.96, 1.14) 1.04 (0.95, 1.13) 0.39
> 7 1.14 (1.05, 1.24) 1.07 (0.97, 1.18) 1.06 (0.97, 1.17) 0.21
% with < high school education
< 11.5 1 1 1
11.5–19.5 1.06 (0.97, 1.15) 0.94 (0.85, 1.04) 0.95 (0.86, 1.05) 0.29
≥ 19.5 1.20 (1.10, 1.30) 0.97 (0.86, 1.09) 0.97 (0.87, 1.10) 0.66
Smoking (current) 1.13 (0.98, 1.30) — 0.98 (0.85, 1.13) 0.81
BMI (kg/m2)
19- < 25 1 — 1
25–29 0.99 (0.91, 1.10) — 1.01 (0.92, 1.12) 0.78
≥ 30 1.16 (1.06, 1.27) — 1.10 (1.01, 1.21) 0.04
Platelet count (×103/μL)
≤ 207 1 — 1
208–277 1.23 (1.13, 1.34) — 1.10 (1.01, 1.20) 0.04
≥ 278 1.41 (1.30, 1.53) — 1.15 (1.05, 1.26) 0.003
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Table 2 Prevalence ratios of poor glycemic control (HbA1c >7 % vs. ≤7 %)a (Continued)
White blood cell count (1000 per μL)
< 6.3 1 — 1
6.3–8.2 1.20 (1.10, 1.30) — 1.11 (1.02, 1.21) 0.02
> 8.2 1.33 (1.22, 1.44) — 1.18 (1.08, 1.29) <0.001
Ferritin (ng/mL)
< 200 1 — 1
200–399 1.04 (0.96, 1.14) — 1.02 (0.93, 1.11) 0.67
≥ 400 1.25 (1.16, 1.36) — 1.17 (1.08, 1.27) <0.001
Total cholesterol (mg/dL)
≤ 200 1 — 1
201–239 1.42 (1.28, 1.59) — 1.12 (0.97, 1.26) 0.13
≥ 240 1.65 (1.44, 1.89) — 1.12 (1.01, 1.29) 0.04
HDL (mg/dL)
≤ 40 1 — 1
40–59 0.79 (0.71, 0.88) — 0.82 (0.73, 0.91) <0.001
≥ 60 0.70 (0.63, 0.77) — 0.68 (0.60, 0.76) <0.001
Triglycerides (mg/dL)
≤ 150 1 — 1
150–199 1.14 (1.05, 1.25) — 1.14 (1.05, 1.25) 0.004
≥ 200 1.51 (1.39, 1.63) — 1.48 (1.35, 1.61) <0.001
Systolic blood pressure (mm Hg)
< 120 1 — 1
120–139 1.07 (0.94, 1.22) — 1.02 (0.89, 1.16) 0.81
≥ 140 1.33 (1.18, 1.48) — 1.12 (1.01, 1.26) 0.04
Albumin (g/dL)
≤ 3.5 1 — 1
3.6–3.9 0.91 (0.84, 0.98) — 0.93 (0.86, 1.00) 0.05
≥ 4.0 0.76 (0.69, 0.83) — 0.76 (0.69, 0.84) <0.001
Normalized protein catabolic rate (g/kg/d)
< 0.8 1 — 1
0.8–1.00 0.82 (0.75, 0.90) — 0.82 (0.76, 0.90) <0.001
≥ 1.01 0.84 (0.78, 0.91) — 0.85 (0.79, 0.92) <0.001
eGFR f (mL/min/1.73 m2)
< 7 1 — 1
7–10 1.25 (1.13, 1.38) — 1.16 (1.04, 1.29) 0.009
≥ 10 1.10 (0.98, 1.22) — 1.38 (1.25, 1.53) <0.001
Hemoglobin (g/dL)
< 10 1 — 1
10–11 1.17 (0.98, 1.38) — 1.17 (0.99, 1.39) 0.18
≥ 11 1.40 (1.21, 1.61) — 1.11 (0.99, 1.24) 0.09
aIn 16,297 US adult patients with diabetes mellitus initiating maintenance hemodialysis at a DaVita outpatient facility
bModel 1 included demographic and area-level socioeconomic variables
cModel 2 was a multivariable model that included all demographic, area-level socioeconomic, and clinical and biometric variables
dP values correspond to significance values for Model 2
eCompared with white race as the reference category
feGFR, estimated glomerular filtration rate
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Table 3 Prevalence ratios of poor glycemic control
(HbA1c >7 % vs. ≤7 %) by diabetes type
Determinants Type 1a P-value Type 2b P-value
Age (years)c
Tertile 1 1 1
Tertile 2 1.31 (0.95, 1.80) 0.10 0.78 (0.72, 0.84) <0.001
Tertile 3 1.04 (0.76, 1.70) 0.81 0.57 (0.52, 0.62) <0.001
Male sex 0.94 (0.71, 1.24) 0.67 1.08 (1.00, 1.16) 0.05
Race/ethnicityd
Native American 1.03 (0.52, 2.05) 0.93 1.47 (1.20, 1.79) <0.001
Asian 0.48 (0.11, 2.05) 0.32 1.00 (0.80, 1.25) 0.99
Black 0.82 (0.58, 1.16) 0.27 1.04 (0.95, 1.14) 0.44
Pacific Islander 0.78 (0.18, 3.42) 0.75 0.95 (0.61, 1.48) 0.82
Other/Multiracial 0.41 (0.05, 3.07) 0.38 0.79 (0.38, 1.67) 0.53
Hispanic ethnicity 0.75 (0.51, 1.11) 0.15 1.18 (1.06, 1.31) 0.002
Median rent ($)
≤ 735 1 1
736–959 0.79 (0.57, 1.08) 0.14 0.94 (0.86, 1.03) 0.18
≥ 960 0.81 (0.53, 1.23) 0.33 0.99 (0.89, 1.10) 0.87
Median household income ($)
< 38,629 1 1
38,630–52,301 1.17 (0.79, 1.75) 0.43 1.07 (0.97, 1.19) 0.19
> 52,303 1.02 (0.60, 1.81) 0.94 1.11 (0.97, 1.27) 0.14
% below poverty
< 12 1 1
12–21 0.86 (0.56, 1.32) 0.49 1.07 (0.96, 1.20) 0.22
≥ 21 0.86 (0.49, 1.53) 0.61 1.10 (0.94, 1.29) 0.22
% unemployed
< 5 1 1
5–7 0.97 (0.68, 1.38) 0.86 1.04 (0.95, 1.13) 0.42
> 7 1.16 (0.79, 1.69) 0.45 1.05 (0.95, 1.16) 0.30
% with < high school education
< 11.5 1 1
11.5–19.5 0.83 (0.57, 1.21) 0.33 0.96 (0.87, 1.07) 0.45
≥ 19.5 0.94 (0.67, 1.46) 0.80 0.98 (0.87, 1.11) 0.80
Smoking (current) 1.06 (0.69, 1.61) 0.80 0.97 (0.83, 1.12) 0.67
BMI (kg/m2)
19- < 25 1 1
25–29 1.23 (0.88, 1.72) 0.28 1.03 (0.93, 1.14) 0.60
≥ 30 0.86 (0.62, 1.21) 0.39 1.14 (1.04, 1.26) 0.008
Platelet count (×103/μL)
≤ 207 1 1
208–277 1.68 (1.03. 2.74) 0.04 1.08 (0.99, 1.18) 0.08
≥ 278 2.28 (1.42, 3.63) <0.001 1.10 (1.01, 1.21) 0.04
White blood cell count (1000 per μL)
< 6.3 1 1
6.3–8.2 1.01 (0.71, 1.45) 0.94 1.11 (1.02, 1.22) 0.02
Table 3 Prevalence ratios of poor glycemic control
(HbA1c >7 % vs. ≤7 %) by diabetes type (Continued)
> 8.2 0.97 (0.70, 1.38) 0.86 1.19 (1.08, 1.31) <0.001
Ferritin (ng/mL)
< 200 1 1
200–399 0.90 (0.62, 1.31) 0.59 1.01 (0.93, 1.11) 0.77
≥ 400 1.11 (0.80, 1.55) 0.53 1.15 (1.06, 1.26) 0.001
Total cholesterol (mg/dL)
≤ 200 1 1
201–239 1.07 (0.74, 1.54) 0.73 1.12 (0.99, 1.26) 0.06
≥ 240 1.12 (1.09, 1.61) 0.02 1.17 (1.03, 1.34) 0.01
HDL (mg/dL)
≤ 40 1 1
40–59 0.93 (0.64, 1.34) 0.70 0.82 (0.72, 0.92) <0.001
≥ 60 0.72 (0.47, 1.11) 0.14 0.68 (0.60, 0.77) <0.001
Triglycerides (mg/dL)
≤ 150 1 1
150–199 1.23 (0.87, 1.75) 0.25 1.14 (1.04, 1.25) 0.007
≥ 200 1.45 (1.03, 2.05) 0.03 1.48 (1.35, 1.62) <0.001
Systolic blood pressure (mm Hg)
< 120 1 1
120–139 1.34 (0.74, 2.42) 0.33 1.00 (0.88, 1.15) 0.97
≥ 140 1.21 (0.72, 2.05) 0.47 1.12 (0.99, 1.26) 0.07
Albumin (g/dL)
≤ 3.5 1 1
3.6–3.9 0.76 (0.58, 1.03) 0.08 0.94 (0.87, 1.02) 0.15
≥ 4.0 0.81 (0.54, 1.22) 0.30 0.76 (0.69, 0.85) <0.001
Normalized protein catabolic rate (g/kg/d)
< 0.8 1 1
0.8–1.00 1.18 (0.84, 1.65) 0.33 0.80 (0.73, 0.88) <0.001
≥ 1.01 1.09 (0.81, 1.49) 0.57 0.83 (0.77, 0.90) <0.001
eGFR e (mL/min/1.73 m2)
< 7 1 1
7–10 1.59 (1.04, 2.43) 0.03 1.14 (1.01, 1.27) 0.03
≥ 10 1.66 (1.13, 2.43) 0.009 1.36 (1.23, 1.51) <0.001
Hemoglobin (g/dL)
< 10 1 1
10–11 0.95 (0.57, 1.61) 0.86 1.21 (0.98, 1.45) 0.07
≥ 11 1.03 (0.68, 1.57) 0.90 1.45 (1.00, 1.70) 0.05
aIn 627 US adult patients with type 1 diabetes mellitus initiating maintenance
hemodialysis at a DaVita outpatient facility. Multivariable model included all
demographic, area-level socioeconomic, and clinical and biometric variables
bIn 15,670 US adult patients with type 2 diabetes mellitus initiating maintenance
hemodialysis at a DaVita outpatient facility. Multivariable model included all
demographic, area-level socioeconomic, and clinical and biometric variables
cAge breakdown in tertiles was as follows: 18–31 (tertile 1), 32–36 (tertile 2), 37–39
(tertile 3) for patients with type 1 diabetes, and 40–61 (tertile 1), 62–71 (tertile 2),
and >71 (tertile 3) for patients with type 2 diabetes
dCompared with white race as the reference category
eeGFR, estimated glomerular filtration rate
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frailty [21]. In older patients who were classified as hav-
ing type 2 diabetes, we found that BMI was positively as-
sociated with poor glycemic control while markers for
malnutrition such as albumin and nPCR were inversely
associated with poor control. However, these variables
were not associated with poor glycemic control among
younger patients who were classified as having type 1
diabetes. Although variables such as Native American
race, Hispanic ethnicity, and clinical variables including
white blood cell count, ferritin, HDL, and SBP were not
associated with poor glycemic control in patients with
type 1 diabetes as they were in the overall cohort, this
could be due to small sample size of patients with type 1
diabetes in our cohort (4 % of the overall cohort) and
the lack of power to detect true associations.
Given racial and ethnic differences in the development
and progression of diabetes complications [22], we ex-
pected the prevalence of poor glycemic control to be
higher in minorities compared with non-Hispanic
whites. However, multivariable-adjusted models demon-
strated that the prevalence of poor glycemic control was
only higher in Native American and Hispanic patients
compared with that in non-Hispanic white patients, after
adjusting for five area-level socioeconomic indicators.
Interestingly, we found that poor glycemic control was
not associated with any of the five area-level socioeco-
nomic variables that were examined in fully adjusted
models. Findings were not sensitive to adjustment for
several variables that could be hypothesized to lie on the
potential causal pathway between socioeconomic factors
and poor HbA1c control including BMI, metabolic and
inflammatory markers. Our findings contrast with other
studies in which associations between socioeconomic
factors and poor HbA1c control were found [23, 24].
However, the effects of socioeconomic status may be
blunted in an insured population such as that of Medi-
care beneficiaries with ESRD, who are seen regularly or
at least monthly by a nephrologist, in which financial
barriers to health care are not as prominent.
Our observation that an atherogenic lipoprotein profile
and components of metabolic syndrome, including BMI,
HDL, triglycerides, and blood pressure, were associated
with poor glycemic control is consistent with earlier stud-
ies [11, 25–28]. Since ours is a cross-sectional study, we
cannot infer causality; however, either direction of causal-
ity would have critical clinical implications in hemodialysis
patients with diabetes among whom cardiovascular dis-
ease is a major cause of morbidity and mortality [29].
Our data suggest that poor glycemic control is associ-
ated with markers of increased inflammation and infec-
tion, independent of BMI. These findings are supported
by previous studies that have found relations between
hyperglycemia and inflammation and endothelial dysfunc-
tion [30]. Although it would have been ideal to assess the
relation of systemic inflammation with glycemic control
using C-reactive protein (CRP) as a marker for inflamma-
tion, we were not able to do so due to data on CRP being
unavailable for a majority of the patients since it is not
measured routinely in the care of these patients.
We found that higher eGFR at initiation of dialysis
was associated with poor glycemic control, suggesting
that sicker patients in uremic state who initiate dialysis
earlier (i.e., with more preserved kidney function) may
present with higher HbA1c levels. Previous studies have
reported that uremic toxins influence glucose homeosta-
sis by increasing insulin resistance, promoting hepatic
gluconeogenesis, and suppressing peripheral glucose
utilization in ESRD patients [31]. Another explanation
could be that patients with a higher eGFR have lower
creatinine production, a marker for lower muscle mass
and malnutrition which are known to be involved in the
pathogenesis of diabetes [32]. Grootendorst et al. [33]
found that higher eGFR was associated with a higher
mortality and reasoned that while plasma creatinine is
determined by GFR and muscle mass, in patients with
impaired renal function, such as those with ESRD,
muscle mass becomes the more important determinant
of plasma creatinine with declining GFR. The authors
showed that eGFR was inversely associated with muscle
mass and this association was particularly stronger in
patients with diabetes [33].
We were not surprised by the finding that higher albu-
min levels were associated with improved glycemic con-
trol. There have been previous reports of excess
mortality in ESRD patients being attributed to low
serum albumin levels, potentially a proxy for malnutri-
tion, which are independent predictors of morbidity and
mortality in this patient population [34, 35]. These find-
ings about protein malnutrition and glycemic control
were further substantiated by nPCR data from which we
found that patients in the highest tertile of nPCR had
better glycemic control compared with those in the low-
est tertile, particularly for patients with type 2 diabetes.
While low serum album levels may represent malnutri-
tion arising from uremic syndrome, they may also be a
marker of comorbidities and inflammation more gener-
ally, indicative of a more serious systemic disease [36].
Hence, the association we observed between serum albu-
min and HbA1c is in line with our findings that support
the relation of inflammation with poor glycemic control,
and the association between HbA1c and eGFR at initi-
ation of dialysis which may be representative of a more
serious disease status.
Whether HbA1c accurately reflects mean blood glucose
levels in patients with diabetes on hemodialysis is some-
what controversial, as some would argue that it may not
be a reliable marker for long-term glycemic control [37].
Dialysis patients have shorter erythrocyte lifespan, and
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low concentrations of erythrocytes in those with anemia
or the predominance of younger erythrocytes observed in
patients who are on iron replacement therapy or
erythropoiesis-stimulating agents can result in falsely low
HbA1c values, underestimating the patient’s glycemic
state [38]. While some studies have advocated the use of
glycated albumin and fructosamine as alternative mea-
sures of glycemic control in dialysis patients, these
markers are easily influenced by various physiological con-
ditions [38]. Moreover, the within-subject variation of
fructosamine is higher than that of HbA1c, and the use of
fructosamine as a marker for glycemic control would de-
pend on normal serum albumin levels, which are rarely
observed in dialysis patients [38]. In the absence of con-
sistent and ample clinical data supporting the use of gly-
cated albumin and fructosamine as potential markers of
glycemic control, it would be reasonable to use HbA1c as
the reference standard for hemodialysis patients with
diabetes.
Our study has some limitations. Due to the cross-
sectional design of the study, we cannot establish direc-
tionality of the observed associations. Prospective epi-
demiological studies are needed to address the question of
whether these sociodemographic and clinical factors lead
to higher HbA1c levels or whether poor glycemic control
leads to these risk factors. We also cannot rule out poten-
tial residual confounding due to the observational nature
of the study. Furthermore, we could not determine and
adjust for the severity of comorbidities because these data
were abstracted from an administrative database. Lastly,
the USRDS does not reliably distinguish between type 1
and type 2 diabetes. We used the occurrence of diabetes
in patients of ages <40 and ≥40 years as a surrogate for
type 1 and type 2 diabetes respectively, but there is some
diagnostic uncertainty in using this imperfect approach to
making the distinction between type 1 and type 2 diabetes,
especially in light of the fact that there is a growing fre-
quency of type 2 diabetes in younger patients [39] and that
patients with type 1 diabetes may have reached ESRD after
40 years of age. Despite these limitations, the study herein
takes advantage of two unusually large and detailed data
sources to characterize patients according to a wide array
of demographic and socioeconomic factors as well as clin-
ical parameters, and to assess associations between these
variables and HbA1c control.
Conclusion
Our findings indicate that while patient’s age, race, eth-
nicity are risk factors for higher prevalence of poorly
controlled HbA1c, most determinants of poor glycemic
control are clinically-relevant factors, including BMI,
atherogenic lipid profile, high blood pressure, inflamma-
tion, and markers indicative of malnutrition and a more
serious systemic disease.
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